Can an immune booster make CAR-T therapy last longer in myeloma?

NCT ID NCT07200089

Recruiting now Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 22, 2026 · Updated 3 times

Summary

This early-stage trial tests whether adding a drug called NT-I7 (a lab-made immune booster) can help CAR-T cells survive longer in people with multiple myeloma that has come back or stopped responding to treatment. About 52 participants who are already getting standard CAR-T therapy will receive either NT-I7 or a placebo. The main goal is to check safety and find the best dose, while also seeing if the drug improves the cancer-fighting power of CAR-T cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NT-I7 (recombinant human IL-7, also called Efineptakin alfa)
What this could lead to: If it works, this could help CAR-T cells last longer in the body, potentially improving control of multiple myeloma and delaying relapse.
What could go wrong: This is a very early Phase 1 trial with only 52 people, so it's too soon to know if it works. The drug may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA MULTIPLE MYELOMA IN RELAPSE MULTIPLE MYELOMA REFRACTORY

Contacts and locations

Locations

Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.